Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer
and inflammatory diseases. Although the evolution of its clinical application could not have …

Several haematological malignancies, including multiple myeloma (MM) and acute myeloid
leukaemia (AML), have well-defined precursor states that precede the development of overt …

Methods of treating, preventing and/or managing cancer as well as and diseases and
disorders associated with, or characterized by, undesired angiogenesis are disclosed …

Over the past 50 years, thalidomide has been a target of active investigation in both
malignant and inflammatory conditions. Although initially developed for its sedative …

Background: Thalidomide is best known as a major teratogen that caused birth defects in up
to 12,000 children in the 1960s. More recently, this agent has been approved by the US …

MDS is characterized by ineffective hematopoiesis that leads to peripheral cytopenias.
Development of effective treatments has been impeded by limited insight into pathogenic …

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis that leads
to peripheral cytopenias. We observed that SMAD7, a negative regulator of transforming …

Even though myelodysplastic syndromes (MDS) are characterized by ineffective
hematopoiesis, the molecular alterations that lead to marrow failure have not been well …

Multiple myeloma (MM) is a clonal plasma cell disorder frequently accompanied by
hematopoietic impairment. We show that hematopoietic stem and progenitor cells (HSPCs) …

Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being
investigated extensively in the management of advanced cancer. Multiple studies with large …